Publications by Patrycja Nowak-Sliwinska

Towards Light-Activated Ruthenium-Arene (RAPTA-Type) Prodrug Candidates

Paul Joseph Dyson, Rosario Scopelliti, Felix Daniel Bobbink, Patrycja Nowak-Sliwinska, Anna Katherine Renfrew

Cancer is currently one of the deadliest diseases worldwide. Based on the high incidence of this disease, the side effects associated with current chemotherapies and the appearance of drug resistance, considerable efforts have been directed towards the dev ...

WILEY-V C H VERLAG GMBH2019

Helical equilibrium magnetohydrodynamic flow effects on the stability properties of low-n ideal external-infernal modes in weak shear tokamak configurations

Wilfred Anthony Cooper, Jonathan Graves, Patrycja Nowak-Sliwinska, Daniele Brunetti, Alberto Mariani

The impact of equilibrium helical flows on the stability properties of low shear tokamak plasmas is assessed. The corrections due to such helical flow to the equilibrium profiles (mass density, pressure, Shafranov shift, magnetic fluxes) are computed by mi ...

IOP PUBLISHING LTD2019

Recent Considerations in the Application of RAPTA-C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies

Paul Joseph Dyson, Patrycja Nowak-Sliwinska, Magdalena Rausch

The organometallic ruthenium(II) [Ru(arene)Cl2PTA] PTA - 1,3,5-triaza-7-phosphaadamantane compound, RAPTA-C, represents an innovative anti-cancer therapeutic and a better-tolerated alternative to platinum (Pt)-based chemotherapeutic drugs in the treatment ...

WILEY2019

Validation of the ICRF antenna coupling code RAPLICASOL against TOPICA and experiments

Olivier Sauter, Basil Duval, Stefano Coda, Timothy Goodman, Yves Martin, Jean-Marc Moret, Duccio Testa, Patrick Blanchard, Bruno Marchand, Holger Reimerdes

In this paper we validate the finite element code RAPLICASOL, which models radiofrequency wave propagation in edge plasmas near ICRF antennas, against calculations with the TOPICA code. We compare the output of both codes for the ASDEX Upgrade 2-strap ante ...

IOP Publishing Ltd2019

Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug

Paul Joseph Dyson, Patrycja Nowak-Sliwinska, Wee Han Ang

The cytotoxicity of cisplatin (cDDP) is enhanced when co-administered with ethacrynic acid (EA), a glutathione S-transferase (GST) inhibito r. A Pt-lV EA conjugate containing a cDDP core and two axial ethacrynate ligands (compound 1) was shown to be an ex ...

2018

Consensus guidelines for the use and interpretation of angiogenesis assays

Patrycja Nowak-Sliwinska, Michele De Palma, George Coukos, Elizabeth Anne Allen, Yan Gong

The formation of new blood vessels, or angiogenesis, is a complex process that plays important roles in growth and development, tissue and organ regeneration, as well as numerous pathological conditions. Angiogenesis undergoes multiple discrete steps that ...

2018

Current Trends in Multidrug Optimization: An Alley of Future Successful Treatment of Complex Disorders

Patrycja Nowak-Sliwinska

The identification of effective and long-lasting cancer therapies still remains elusive, partially due to patient and tumor heterogeneity, acquired drug resistance, and single-drug dose-limiting toxicities. The use of drug combinations may help to overcome ...

Sage Publications Inc2017

Combination of ruthenium(II)-arene complex [Ru(eta(6)-p-cymene)Cl-2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity

Paul Joseph Dyson, Patrycja Nowak-Sliwinska, Ume-Gulsoom Abdul, Patrick Meraldi

Ruthenium-based compounds show strong potential as anti-cancer drugs and are being investigated as alternatives to other well-established metal-based chemotherapeutics. The organometallic compound [Ru(eta(6)-p-cymene) Cl-2(pta)], where pta = 1,3,5-triaza-7 ...

Nature Research2017

Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment

Paul Joseph Dyson, Patrycja Nowak-Sliwinska, Ume-Gulsoom Abdul, Marije Trudi Te Winkel

Cancer cells are often dependent on epigenetic pathways for their survival. Consequently, drugs that target the epigenome, rather than the underlying DNA sequence, are currently attracting considerable attention. In recent years, the first epigenetic drugs ...

Springer Verlag2017

Drug Combination for Treatment of Proliferative Diseases

Paul Joseph Dyson, Patrycja Nowak-Sliwinska, Hubert van den Bergh

Angiogenesis inhibitory drug combination obtained according to a specific algorithm, preferably a FSC, in which an initial combination of drugs is iteratively adjusted. The drug combination according to the invention may advantageously comprise a RAPTA-C c ...

2017